Large-scale microfluidic bioprocessing platform for cell and gene therapy manufacturing

点击翻译按钮获取中文摘要

MicrofluidX develops and manufactures a system for the production of cell and gene therapies (CGTs). CGTs are an advanced therapy which relies upon complex biological systems (cells, viruses or genetic vector systems) to perform corrective action in patients. This technology has demonstrated an unparalleled healing potential, from multiple types of cancers, to diabetes, and rare diseases. These emerging therapies substantially differ from existing drugs or biologics in that they are a live product with unique development and manufacturing considerations. Existing manufacturing solutions have largely relied on modifying existing biopharma approaches which do not always meet the conditions these therapies require for effective manufacturing. Typically, these therapies are extremely expensive and difficult to produce and average a list price of \>$300k per treatment. These cost constraints, together with the limited production capacity, force public health systems like the NHS to restrict the use to a limited number of patients, and will prevent or delay certain treatments reaching the market if the price points are too high. Key to enabling access to these treatments is therefore to develop a low-cost, robust and scalable manufacturing platform. MicrofluidX is developing a system that cuts costs by up to 90%, enables faster scale-up from discovery to market, and provides more control over manufacturing parameters for a safer end product.